Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTAHIST vs BEPADIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
Angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion.
Symptomatic relief of allergic rhinitis,Urticaria,Off-label: motion sickness,Off-label: insomnia
Hypertension,Diabetic nephropathy in patients with type 2 diabetes and hypertension,Heart failure (NYHA class II-IV) as adjunctive therapy,Stroke prevention in hypertensive patients with left ventricular hypertrophy
1.34 mg (one capsule) orally twice daily.
5 mg orally once daily, increased at 2-week intervals to a maximum of 10 mg once daily if needed.
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment
Hepatic metabolism via CYP450 enzymes (primarily CYP3A4 and CYP2D6); major metabolite is inactive.
Primarily metabolized by CYP2C9 to inactive metabolites; also undergoes glucuronidation.
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
Primarily renal excretion (70-80% unchanged) with minor biliary/fecal elimination (10-15%)
92% bound to albumin.
95-98% bound primarily to albumin
0.9 ± 0.3 L/kg, indicating extensive extravascular distribution.
0.2-0.4 L/kg indicating moderate tissue distribution
Oral: 68% ± 12% due to first-pass metabolism.
Oral: 60-75%; complete with IV administration
No dose adjustment required for mild to moderate renal impairment. Safety not established for severe impairment (GFR <30 m L/min).
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, reduce dose by 50% or increase dosing interval to every other day.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C).
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use not recommended.
Not indicated for pediatric patients under 12 years of age. Safety and efficacy not established.
Not approved for pediatric use.
No specific dose adjustment recommended; monitor for increased anticholinergic effects and cognitive impairment.
Initiate at 2.5 mg once daily; titrate slowly due to increased sensitivity and risk of falls.
None.
None
May cause drowsiness; caution when driving or operating machinery. Avoid alcohol. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or urinary retention. Geriatric patients more sensitive to anticholinergic effects. Pediatric patients <6 years: not recommended.
Fetal toxicity: Use in pregnancy can cause fetal harm; discontinue as soon as possible when pregnancy is detected,Hypotension in volume-depleted patients,Renal function deterioration in patients with bilateral renal artery stenosis or single kidney,Hyperkalemia, especially in renal impairment or concomitant use of potassium-sparing diuretics,Avoid use with aliskiren in patients with diabetes
Hypersensitivity to any component. Newborns or premature infants. Breastfeeding (contraindicated due to risk of adverse effects in infants). Concomitant use with MAOIs.
Pregnancy (second and third trimesters),Hypersensitivity to bepadin or any component,Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR <60 m L/min)
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) if taking MAOIs. Grapefruit juice may increase phenylephrine absorption; limit intake.
No significant food interactions reported. Grapefruit juice does not affect bepotastine metabolism. Avoid excessive alcohol intake due to potential for increased sedation.
ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk from vasoconstrictive effects (phenylephrine) possibly reducing uterine blood flow; avoid if possible. Second/third trimester: phenylephrine may cause fetal hypoxia via placental vasoconstriction; use only if benefit outweighs risk. No known structural teratogenicity.
Limited data in humans. In animal studies, no teratogenic effects at therapeutic doses. Increased risk of fetal loss and reduced fetal weight at toxic doses. First trimester: avoid unless benefit outweighs risk. Second/third trimester: use with caution; may cause fetal bradycardia and hypotension.
Brompheniramine is excreted in breast milk in small amounts; M/P ratio not established. Phenylephrine has minimal excretion. Due to anticholinergic effects, may reduce milk production or cause sedation in infants. Use caution; prefer non-sedating alternatives if possible.
Not known if excreted in human milk. M/P ratio not established. Caution advised; consider risk-benefit. Monitor infant for excessive sedation and feeding difficulties.
No specific pharmacokinetic studies. Increased plasma volume and renal clearance in pregnancy may reduce drug levels, but efficacy threshold remains. No dose adjustment recommended; use the lowest effective dose for shortest duration due to potential risks.
No standard dose adjustment recommended; however, increased renal clearance and volume of distribution may require dose increase or more frequent administration. Monitor clinical response and adjust based on therapeutic drug monitoring if available.
Actahist is a combination antihistamine-decongestant (chlorpheniramine/phenylephrine). Avoid in patients with hypertension, severe coronary artery disease, or MAOI use. Monitor for sedation and urinary retention, especially in elderly males with BPH.
BEPADIN (bepotastine besilate), a second-generation antihistamine, is indicated for allergic rhinitis and urticaria. It does not require hepatic metabolism, making it suitable for patients with liver impairment. Onset of action is within 1 hour. Avoid concurrent use with CNS depressants due to additive sedative effects.
Take with food or milk to reduce stomach upset.,Avoid alcohol and CNS depressants as they can increase drowsiness.,Do not drive or operate machinery until you know how this medication affects you.,Contact your doctor if you experience chest pain, rapid heartbeat, or difficulty urinating.
Take once daily in the morning or as directed by your physician.,Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause drowsiness.,Avoid alcohol consumption as it can intensify drowsiness.,Report any severe allergic reactions, such as difficulty breathing or swelling, to your healthcare provider immediately.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTAHIST vs BEPADIN, answered by our medical review team.
ACTAHIST is a Antihistamine that works by Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.. BEPADIN is a Ophthalmic Antihistamine that works by Angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTAHIST and BEPADIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTAHIST is: 1.34 mg (one capsule) orally twice daily.. The standard adult dose of BEPADIN is: 5 mg orally once daily, increased at 2-week intervals to a maximum of 10 mg once daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTAHIST and BEPADIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTAHIST is classified as Category C. ACTAHIST (brompheniramine/phenylephrine) pregnancy category C. Inadequate human data; animal studies show no malformations at therapeutic doses. First trimester: theoretical risk f. BEPADIN is classified as Category C. Limited data in humans. In animal studies, no teratogenic effects at therapeutic doses. Increased risk of fetal loss and reduced fetal weight at toxic doses. First trimester: avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.